Trial Profile
An Open-label, Multicenter, Randomized Study to Determine Dose Conversion Factors at Different Frequencies of Administration After Switching From Maintenance Treatment With Intravenous Epoetin Alfa to Maintenance Treatment With Intravenous RO0503821 in Hemodialysis Patients With Chronic Renal Anemia.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Dec 2016
Price :
$35
*
At a glance
- Drugs Methoxy polyethylene glycol-epoetin beta (Primary)
- Indications Anaemia
- Focus Pharmacodynamics
- Sponsors Roche
- 27 Jan 2014 New trial record